Dr. John Edwards is co-director of the stem cell transplantation program at Indiana Blood & Marrow Transplantation at Franciscan St. Francis Health.
Recent Publications include:
Ingersoll SB, Ahmad S, Stoltzzfus GP, Patel S, Radi MJ, Finkler NJ, Edwards JR, Holloway RW. Functional Characterization of a Fluorescent Highly Tumorigenic Ovarian Cancer Line to Test Cellular Therapy in Experimental Models. International Journal of Gynecologic Oncology 2011.
Ingersoll SB, Ahmad S, Thoni N, Ahmed N, Monohan K and Edwards JR. Targeting the II6-Pathway in Multiple Myeloma and Its Implications in Cancer-Associated Gene Hypermethylation. Med Chem 2011 Sep;7(5):473-9.
Ingersoll SB, Stoltzfuz S, Merchant MH, Ahmad S, Ciomeck NA, Edwards C, Finkler NJ, Holloway RW, Edwards JR. Evaluation of the Cytoxic Response Against Ovarian Cancer by Immune Effector Cells Isolated and Expanded from Healthy Donors vs. Patients or Cord Blood. International Society for Cell Therapy (ISCT). Rotterdam Netherlands. May 18, 2011.
Bash R, Ingersoll SB, Sankpal UT, Ahmad S, Baker CH, Edwards JR, Holloway RW, Kaja S, Abdelrahim M. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and surviving through suppressing specificity protein transcription factors. Gynecol Oncol 2011 Jul;122(1):163-70. Epub 2011 Apr 15.
Crout CA, Koh LP, Gockerman JP, Moore JO, Decastro C, Long, GD, Diehl L, Gasparetto C, Niedzwiecki D, Edwards JR, Prosnitz L, Horwitz M, Chute J, Morris A, Davis P, Beaven A, Chao NJ, Ali-Osman F, Rizzieri DA. Overcoming Drug Resistance in Mantle Cell Lymphoma Using a Combination of Dose Dense and Intense Therapy Cancer Investigation 2010 Jul;28(6):654-60.
Stiff PJ,Agovi MA, Antman KH, Blaise D, Camitta BM, Cairo MS, Childs RW, Edwards JR, Gale RP, Hale GA, Lazarus HM, Arora M. High-Dose Chemotherapy with Blood or Bone Marrow Transplants for Rhabdomysarcoma. Biol Blood and Marrow Transplant 2010 Apr;16(4):525-32.
Ingersoll SB, Ahmad S, Patel S, Edwards D, Patel D, Caballero L, Holloway RW, Edwards JR. Functional characterization of a fluorescent highly tumorigenic cell line to use in an animal model of ovarian cancer. (abstract) Gynecologic Oncology 112(2009), S104-105.
Ingersoll SB, Patel S, Caballero L, Ahmad S, Edwards D, Holloway RW, Edwards JR. Synergistic cytotoxicity of interferon alpha-2b and interleukin-2 in combination with PBMC against ovarian cancer: development of an experimental model for cellular therapy. Gynecologic Oncology 2009 Jan;112(1):192-98.
Gardner SL, Carreras J, Boudreau C, Camitta BM, Adams RH, Chen AR, Davies SM, Edwards JR, Groves AC, Hale GA, Lazarus HM, Arora M, Stiff PJ, Eapen M. Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma. Bone Marrow Transplant 2008 May;41(10):867-72.
Ingersoll SB, Patel S, Monahan K, Caballero L, De Nardis SA, Ahmad S, Holloway RW, Edwards JR. Synergistic Cytotoxicity of IFNa-2b and IL-2 in Combination with PBMC against Ovarian Cancer: Development of an Experimental Model for Cellular Therapy. Society of Gynecologic Oncologists Annual Meeting, Tampa FL March 2008.